Patents Issued in June 8, 2017
  • Publication number: 20170157054
    Abstract: The present invention relates to formulations of a pharmacological effective fat-soluble active ingredient with a high bioavailability of said fat-soluble active ingredient as well as to their manufacture and use as dietary supplement, food, feed, personal care product and/or pharmaceutical. Such formulations are those which when dissolved, dispersed or diluted in/with water have an extinction E 1/1 at a wavelength in the range of from 200 to 800 nm, preferably in the range of from 250 to 600 nm, more preferably in the range of from 250 to 500 nm, more preferably in the range of from 370 to 485 nm, of ?380, preferably of ?600, most preferably ?900. In preferred embodiments of the formulations of the present invention such formulations show an extrusion loss of fat-soluble active ingredient of ?30% when pressed to tablets.
    Type: Application
    Filed: February 23, 2017
    Publication date: June 8, 2017
    Inventors: Markus BECK, Hansjoerg GRASS, Bruno LEUENBERGER, Markus NOWOTNY, Christian SCHÄFER, Karl Manfred VOELKER
  • Publication number: 20170157055
    Abstract: An abuse deterrent pharmaceutical composition comprising: (a) an active ingredient; (b) deterrent agent; (c) pH dependent soluble ingredient; and (d) pH modifying agent; wherein deterrent agent is not release in effective amount to produce its intended aversive effect upon correct administration but it release in effective amount to produce its intended aversive effect upon incorrect administration.
    Type: Application
    Filed: June 3, 2015
    Publication date: June 8, 2017
    Inventors: Jayendrakumar Dasharathlal Patel, Shwetaben Dasharathbhai Patel
  • Publication number: 20170157056
    Abstract: Improved oral dosage forms of methyl hydrogen fumarate and prodrugs thereof are disclosed. Methods of treating diseases such as multiple sclerosis and psoriasis using such dosage forms are also disclose.
    Type: Application
    Filed: January 7, 2016
    Publication date: June 8, 2017
    Applicant: XENOPORT, INC.
    Inventors: Sami Karaborni, Sarina Grace Harris Ma, Chen Mao, Ching Wah Chong, Peter Robert Prinz Freed, Mesut Ciper, Stefanie Krenzlin, David J. Wustrow, Peter A. Virsik
  • Publication number: 20170157057
    Abstract: The present invention provides a method for preparing a graft material containing organ or tissue cells, the cells including cells having inhibited PHLDA3 expression.
    Type: Application
    Filed: May 22, 2015
    Publication date: June 8, 2017
    Applicants: Kyoto University, TOHOKU UNIVERSITY, Rieko OHKI
    Inventors: Shoichiro SUMI, Rieko OHKI, Naoaki SAKATA
  • Publication number: 20170157058
    Abstract: The present invention provides an acid resistant capsule shell composition comprising a water-soluble enteric polymer, a water-soluble film forming polymer, a coagulant, and a gelling aid. The water-soluble enteric polymer comprises hydrophobic functional groups and hydrophilic functional groups. The present invention further provides a process for preparing an acid resistant capsule shell comprising: dissolving said acid resistant capsule shell composition in deionized water to form a capsule shell solution; heating then cooling the capsule shell solution to form a capsule shell stock solution; dipping a pin into the capsule shell stock solution then removing the pin to form a film-coated pin; and drying the film-coated pin to form the acid resistant capsule shell. The acid resistant capsule shell has acidic resistance and the process for preparing the acid resistant capsule shell is without organic solvent; hence, the problem of organic solvent residues can be prevented.
    Type: Application
    Filed: December 8, 2015
    Publication date: June 8, 2017
    Inventors: Ruei Jan Chang, Yi Huei Lin, Chieh Jen Wu
  • Publication number: 20170157059
    Abstract: A composition is described having improved oral permeability of polar agents such as neuraminidase inhibitors. The composition includes one or more polar agents and one or more permeability enhancers such that the composition increases the amount of the polar agent capable of being transported across a Caco-2 cell membrane by at least 150% relative to the amount capable of being transported across the Caco-2 Cell membrane in the absence of the permeability enhancer. Oral dosage forms including the composition, and methods of treating or preventing influenza infection are also provided.
    Type: Application
    Filed: February 24, 2017
    Publication date: June 8, 2017
    Applicant: ALA WAI PHARMA, INC.
    Inventors: Eric Holmes, Michael Hite
  • Publication number: 20170157060
    Abstract: An abuse deterrent immediate release coated reservoir solid dosage form that releases the drug at a desired rate for quick onset of action when a single unit or prescribed units of the dosage form are orally administered but exhibits a reduced rate of release when more than the prescribed number of units, are administered.
    Type: Application
    Filed: February 24, 2017
    Publication date: June 8, 2017
    Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
    Inventors: Nitin Bhalachandra DHARMADHIKARI, Yashoraj Rupsinh ZALA, Dilip SHANGHVI
  • Publication number: 20170157061
    Abstract: The present invention is directed to nanoparticulate compositions comprising meloxicam particles having an effective average particle size of less than about 2000 nm.
    Type: Application
    Filed: February 21, 2017
    Publication date: June 8, 2017
    Inventors: Eugene R. Cooper, Tuula Ryde, John Pruitt, Laura Kline
  • Publication number: 20170157062
    Abstract: The present invention relates to oral pharmaceutical dosage forms comprising buprenorphine with the dosage form releasing buprenorphine instantly upon oral, preferably sublingual, application of the dosage form. The present invention also relates to the use of such dosage forms for treating pain in a human or animal or for drug substitution therapy in drug-dependent human subjects.
    Type: Application
    Filed: February 24, 2017
    Publication date: June 8, 2017
    Inventors: Alexander OKSCHE, William HEATH, Timothy HOLDEN, Derek A. PRATER, Richard S. SACKLER, Malcolm WALDEN
  • Publication number: 20170157063
    Abstract: Compositions and methods for maintaining healthy skin and alleviating skin conditions such as redness, inflammation, irritation and skin aging, as well as for maintaining healthy scalp and hair are disclosed. The oral compositions disclosed comprise antioxidants including lycopene, gallic acid and ascorbic acid. Preferably lycopene has been water-extracted, more preferably under acid conditions. In the method of treatment aspect of the invention, an oral composition containing antioxidant(s) is administered to a person concurrently with a topical treatment for said skin conditions. Preferred topical compositions comprise cyclohexane polyols, such as cyclohexanediol or cyclohexanetriol.
    Type: Application
    Filed: February 1, 2017
    Publication date: June 8, 2017
    Inventor: Piotr CHOMCZYNSKI
  • Publication number: 20170157064
    Abstract: The present invention relates to method of treatment of hepatitis C using hexestrol or a derivative thereof. The methods of the present invention can be used in patients with hepatitis C administering hexestrol or a derivative thereof in combination with one or more anti-hepatitis C drugs.
    Type: Application
    Filed: November 30, 2016
    Publication date: June 8, 2017
    Inventors: Geena Malhotra, Kalpana Joshi
  • Publication number: 20170157065
    Abstract: Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD-not otherwise specified (PDD-NOS) or attention deficit/hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein.
    Type: Application
    Filed: July 12, 2016
    Publication date: June 8, 2017
    Inventor: Guy M. Miller
  • Publication number: 20170157066
    Abstract: The present invention provides a pharmaceutical composition for oral administration comprising a D-amino acid combined with an antioxidant selected from the group consisting of vitamin E, vitamin C, a glutathione or a precursor thereof.
    Type: Application
    Filed: February 20, 2017
    Publication date: June 8, 2017
    Applicant: AAS, LLC
    Inventor: Daniel Javitt
  • Publication number: 20170157067
    Abstract: Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.
    Type: Application
    Filed: October 20, 2016
    Publication date: June 8, 2017
    Applicant: SUNOVION PHARMACEUTICALS INC.
    Inventors: Thomas JERUSSI, Qun Kevin FANG, Mark G. CURRIE
  • Publication number: 20170157068
    Abstract: The present invention provides effective and safe medicaments for the treatment of connective tissue diseases of the skin, particularly with respect to the treatment of cutaneous forms of Lupus Erythematous. The medicaments comprise as the therapeutically active ingredient a beta2 adrenoceptor agonist. The invention furthermore relates to dermatological compositions without skin sensitization properties and which contain enantiomerically pure or enriched R-enantiomers of a beta2 adrenoceptor agonist.
    Type: Application
    Filed: February 23, 2017
    Publication date: June 8, 2017
    Inventors: Morten Sloth WEIDNER, Hans Christian WULF
  • Publication number: 20170157069
    Abstract: The present invention relates to a composition for preventing or treating immune diseases through the suppression of B cell activity induced by metformin. More particularly, the present invention relates to a composition comprising a metformin compound or a pharmaceutically acceptable salt thereof as an active ingredient for preventing or treating immune diseases, wherein the composition is characterized by suppression or reduction of B cell activity which is a cause of disease. The present invention can be valuable in the use thereof for various autoimmune diseases as an immunosuppressant which can prevent or treat immune diseases by suppressing or reducing B cell activity and Th17 cell activity, which are causes of disease, or by promoting or increasing regulatory T cell activity.
    Type: Application
    Filed: February 23, 2017
    Publication date: June 8, 2017
    Applicant: CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION
    Inventors: Mi-La CHO, Seon-Yeong LEE, Min-Jung PARK, Jae-Seon LEE, Eun-Ji YANG, Eun-Kyung KIM, Jun-Geol RYU, Hye-Jin SON
  • Publication number: 20170157070
    Abstract: The present invention relates to hydroxy-substituted amino and ammonium derivatives, in particular the compounds of formula (1) or (2), and their medical use, including their use in the treatment, prevention or amelioration of an inflammatory, autoimmune and/or allergic disorder, or a proliferative, neoplastic or dysplastic disease or disorder.
    Type: Application
    Filed: February 17, 2017
    Publication date: June 8, 2017
    Inventors: Georg Schlechtingen, Hans-Joachim Knolker, Tim Friedrichson, Gary Jennings, Tobias Braxmeier
  • Publication number: 20170157071
    Abstract: Described herein are compositions and methods for intravenous administration of acetaminophen at a single dose level of less than about 1000 mg for the treatment or prevention of pain (e.g., postoperative pain) and/or fever.
    Type: Application
    Filed: February 17, 2017
    Publication date: June 8, 2017
    Inventors: Mike Allan Royal, James Bradley Breitmeyer
  • Publication number: 20170157072
    Abstract: According to the invention there is provided N,N-bis-2-mercaptoethyl isophthalamide, or a pharmaceutically acceptable salt or derivative thereof, for use in regenerating ascorbate systemically and thus in the therapeutic treatment of chronic obstructive pulmonary disease.
    Type: Application
    Filed: March 31, 2015
    Publication date: June 8, 2017
    Inventors: Boyd Eugene HALEY, Ragnar Axel Theodor KLINGBERG
  • Publication number: 20170157073
    Abstract: Methods and compositions for activating an EphA receptor can be used for identifying therapeutic agents for cancer.
    Type: Application
    Filed: August 15, 2016
    Publication date: June 8, 2017
    Inventors: Bingcheng Wang, Eugene Myshkin, Hui Miao
  • Publication number: 20170157074
    Abstract: It is intended to provide an in vitro culture medium that allows the in vitro culture of fertilized eggs to progress normally to the blastocyst stage without arresting the development thereof. The normal development rate of a fertilized egg is improved by using 5-aminolevulinic acids represented by the following formula (I) (wherein R1 represents a hydrogen atom or an acyl group, and R2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group, or an aralkyl group) or salts thereof as an agent for improving a normal development rate of a fertilized egg.
    Type: Application
    Filed: July 10, 2015
    Publication date: June 8, 2017
    Inventors: Tohru Tanaka, Motowo Nakajima, Kiwamu Takahashi, Osamu Nakajima
  • Publication number: 20170157075
    Abstract: The present invention provides edible compositions, kits and methods for improving brain function/activity, the composition including at least one alpha brain wave promoting factor including theanine, and at least one neurotransmitter-precursor.
    Type: Application
    Filed: February 28, 2016
    Publication date: June 8, 2017
    Inventor: James Edward Beecham
  • Publication number: 20170157076
    Abstract: Disclosed herein are compositions that are useful in effecting the transdermal delivery of therapeutic agents. More particularly, the disclosed transdermal compositions may include a fatty alcohol (for example, octanol), a terpene (for example, limonene), and an active agent comprising an amine moiety.
    Type: Application
    Filed: July 8, 2016
    Publication date: June 8, 2017
    Inventors: Oron Yacoby-Zeevi, Mara Nemas, Eduardo Zawoznik
  • Publication number: 20170157077
    Abstract: Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.
    Type: Application
    Filed: July 13, 2016
    Publication date: June 8, 2017
    Inventors: Oron Yacoby-Zeevi, Mara Nemas
  • Publication number: 20170157078
    Abstract: This invention teaches the use of chelating agents to diagnose and treat metal toxins in a patient. Chelation agents are given to the mother for the benefit of the baby. Metal toxins such as lead, arsenic, mercury, tin, antimony, aluminum and others are known to cause miscarriages, birth defects, maldevelopment of the organs and tissues and maldevelopment of the brain. Chelation treatments of the mother can prevent these problems in the embryo, fetus and infant. Removal of lead and mercury and other toxins allows improved development of the offspring, both during the chelation and after the chelation is discontinued. Determining whether a mother who has just delivered a baby has elevated levels of heavy metals can also be used to identify the elevated metals of the mother as a possible cause of birth defects.
    Type: Application
    Filed: February 20, 2017
    Publication date: June 8, 2017
    Inventor: Patrick James Baggot
  • Publication number: 20170157079
    Abstract: Disclosed herein are formulations containing carbidopa and optionally levodopa, arginine, and other components that have reduced levels of impurities and toxins, particularly degradation productions. Also disclosed herein are methods of treatment diseases or conditions relating to a loss of dopamine or dopaminergic neurons using such formulations, methods of making such formulations, and kits that include such formulations.
    Type: Application
    Filed: February 21, 2017
    Publication date: June 8, 2017
    Inventor: Oron Yacoby-Zeevi
  • Publication number: 20170157080
    Abstract: The present invention is directed to methods and compositions for the treatment of diverticulosis. It is more specifically directed to compositions including L-glutamine, its salts, or its derivatives, and uses of such compositions in the treatment of diverticulosis. In a method aspect, the present invention provides a method of treating diverticulosis. The method includes ingestion of 0.05 g/kg body weight to 10.0 g/kg body weight of L-glutamine, an L-glutamine salt or an L-glutamine derivative per day by a person who has diverticulosis.
    Type: Application
    Filed: February 10, 2017
    Publication date: June 8, 2017
    Inventor: Yutaka Niihara
  • Publication number: 20170157081
    Abstract: Silage compositions are described herein, as well as methods for their preparation and use. A silage composition may include a fatty acid component comprising at least about 70% saturated fatty acid by weight and a fermented component. The fatty acid component may be present in the silage composition in an amount of at least about 10% by weight of the silage composition.
    Type: Application
    Filed: July 21, 2014
    Publication date: June 8, 2017
    Applicant: BENEMILK OY
    Inventors: Illimar ALTOSAAR, Ilmo Pellervo ARONEN, Craig Cano BEESON, Christopher John BUNTEL
  • Publication number: 20170157082
    Abstract: An extended duration anesthetic includes a short duration local anesthetic in a dilute solution and a long duration local anesthetic. The long duration local anesthetic is maintained in a powdered form until the time of administration. Premeasured quantities of the dilute solution and powdered long duration local anesthetic in a kit allow for quick preparation of a solution with desired concentrations of both short duration local anesthetic and long duration local anesthetic at the time of administration.
    Type: Application
    Filed: December 4, 2015
    Publication date: June 8, 2017
    Inventors: Jeremy Poulsen, Louis Stanfield, Lawrence Volz
  • Publication number: 20170157083
    Abstract: Formulations of a neuroprotective agent for parenteral administration are described herein. The formulation is in the form of a concentrated (supersaturated) solution or a concentrated suspension of microparticles. The suspension medium or the solution solvent carrier may also contain dissolved neuroprotective agent. For the supersaturated solutions, the agent is dissolved a high concentrations of at least about 1% by weight, 5% by weight, 10% by weight, 15% by weight, or 20% by weight in a solvent suitable for parenteral administration. For the concentrated suspension, the microparticles have an effective particle size form about 100 nm to about 5 microns, preferably form about 50 nm to about 3 microns, more preferably from about 10 nm to about 2 microns. The formulations described herein can be used to treat a variety of neurological disease/disorders and/or neurological injury or trauma.
    Type: Application
    Filed: February 21, 2017
    Publication date: June 8, 2017
    Inventors: Sasha H. Bakhru, Bryan E. Laulicht, Edith Mathiowitz, Solomon S. Steiner
  • Publication number: 20170157084
    Abstract: The present invention relates to a method for modulating angiogenesis in a subject in need thereof, which comprises administering an effective amount of composition comprising excavatolide B and a pharmaceutically acceptable carrier to the subject.
    Type: Application
    Filed: December 4, 2015
    Publication date: June 8, 2017
    Applicant: National Sun Yat-sen University
    Inventors: ZHI-HONG WEN, PING-JYUN SUNG, HAN-CHUN HUNG
  • Publication number: 20170157085
    Abstract: A method of treating or preventing depressed mood is describe, such as for treating or preventing postpartum blues or depression or other conditions associated with increased MAO-A levels. The method comprises administering to a subject an antioxidant source at least once between day-1 to day-5 postpartum (or on treatment days 1 to 5 of a non-postpartum regimen); an optional tryptophan composition on the evening of day-3 to day-5, simultaneously or following the antioxidant source; and a tyrosine composition the day after administering the tryptophan composition, for example on day-5.
    Type: Application
    Filed: June 12, 2015
    Publication date: June 8, 2017
    Inventor: Jeffrey H. MEYER
  • Publication number: 20170157086
    Abstract: The present invention relates to a composition for the protection, treatment and repair of cartilage in humans and animal joints. The composition contains a combination of unsaponifiable lipids together with one or more of polyphenols and/or catechins. The composition or kit may contain avocado:soybean unsaponifiables (ASU) and green tea.
    Type: Application
    Filed: February 15, 2017
    Publication date: June 8, 2017
    Inventors: Todd R. Henderson, Louis Lippiello, Charles Filburn, David Griffin
  • Publication number: 20170157087
    Abstract: The invention relates to the use of the compound of general formula 1 or its spatial isomers as an analgesic drug. The compounds have high activity, low toxicity, may be used in medicine.
    Type: Application
    Filed: June 10, 2015
    Publication date: June 8, 2017
    Applicant: Obshestvo S Ogranichennoi Otvetsvennost JU "Leofors"
    Inventors: Ekaterina Vladimirovna KHAID, Alla Viktorovna PAVLOVA, Oksana Stanislavovna MIKHAL'CHENKO, Dina Vladimirovna KORCHAGINA, Tatiana Genrihovna TOLSTIKOVA, Konstantin Petrovich VOLCHO, Veniamin Abramovich KHAZANOV, Nariman Faridovich SALAKHUTDINOV
  • Publication number: 20170157088
    Abstract: Salts of glycopyrrolate, including solid forms and formulations such as topicals thereof, are disclosed. Methods of making glycopyrrolate salts, including formulations such as topicals thereof, and methods of treating hyperhidrosis with salts of glycopyrrolate, and formulations such as topicals thereof, are disclosed.
    Type: Application
    Filed: February 21, 2017
    Publication date: June 8, 2017
    Inventors: John Allan STATLER, Anthony Adrian SHAW, Delphine Caroline IMBERT, Jennifer Leigh NELSON, Patricia ANDRES, Lisa Lynn McQUEEN, Stephan Xander Mattheus BOERRIGTER, Jon Gordon SELBO, Mark Christopher ANDRES
  • Publication number: 20170157089
    Abstract: Methods and compositions provided herein relate to the treatment of cancer. In some embodiments, the compositions have utility in the treatment of cancers including glioblastoma multiforme and lung cancer.
    Type: Application
    Filed: November 30, 2016
    Publication date: June 8, 2017
    Inventors: Jeffrey A. Toretsky, Aykut Uren
  • Publication number: 20170157090
    Abstract: The present invention relates to a pharmaceutical combination for use in the treatment of squamous cell carcinoma, comprising a CDK inhibitor selected from the compounds of formula (I); or a pharmaceutically acceptable salt thereof and one or more antineoplastic agents selected from sorafenib, lapatinib, erlotinib, cisplatin, 5-fluorouracil, docetaxel or cetuximab or a pharmaceutically acceptable salt thereof. The said pharmaceutical combination exhibits synergy when used in the treatment of squamous cell carcinoma of head and neck (SCCHN). The invention also relates to a pharmaceutical composition comprising the said combination and a method for the treatment of squamous cell carcinoma of head and neck (SCCHN), using a therapeutically effective amount of said combination.
    Type: Application
    Filed: July 8, 2016
    Publication date: June 8, 2017
    Inventors: Veena Agarwal, Arun Balakrishnan, Giridharan Periyasamy
  • Publication number: 20170157091
    Abstract: The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides Tmax value of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described. The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a Tmax substantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described.
    Type: Application
    Filed: February 16, 2017
    Publication date: June 8, 2017
    Inventors: Rajesh GANDHI, Sreekanth MANIKONDA, Arun JANA, Sameer Shrinivas KUNTE
  • Publication number: 20170157092
    Abstract: This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.
    Type: Application
    Filed: February 23, 2017
    Publication date: June 8, 2017
    Inventors: Steven L. McKnight, Andrew A. Pieper, Joseph M. Ready, Jef K. De Brabander, Jeffrey M. Zigman
  • Publication number: 20170157093
    Abstract: The present invention provides imidazole derivatives of Formula (I) and pharmaceutically acceptable salts thereof. and their use in the treatment of diseases.
    Type: Application
    Filed: February 21, 2017
    Publication date: June 8, 2017
    Inventors: David Jones, Raju Bore Gowda, Rongyuan Xie
  • Publication number: 20170157094
    Abstract: The invention is a pharmaceutical tablet formulation comprising between about 12.5 mg and 100 mg losartan potassium, between about 6.25 mg and about 50 mg chlorthalidone, and sodium bicarbonate in an amount between about 1.0% and about 10.0% by weight.
    Type: Application
    Filed: November 24, 2014
    Publication date: June 8, 2017
    Applicant: Merck Sharp & Dohme B.V.
    Inventors: Jan-Piet Wijgergangs, Jocominus Antonius Maria Zwinkels, Albert Falivene Aldea
  • Publication number: 20170157095
    Abstract: An allisartan isoproxil solid dispersion, pharmaceutical composition comprising the same and use thereof. The Allisartan Isoproxil solid dispersion consists of Allisartan Isoproxil and a pharmaceutically acceptable carrier material, the carrier material comprising a solubilizing carrier and a surfactant, the mass ratio of Allisartan Isoproxil to the surfactant being 1:0.01˜0.10.
    Type: Application
    Filed: June 30, 2015
    Publication date: June 8, 2017
    Applicant: SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.
    Inventors: Guanhao Ye, Shui Bu
  • Publication number: 20170157096
    Abstract: The present disclosure provides substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes, of Formula I D-M-D??(Formula I) useful as antiviral agents. In certain embodiments disclosed herein M is a group -P-A-P- where A is Certain substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. Pharmaceutical compositions/and combinations containing one or more substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes and a pharmaceutically acceptable carrier are also provided by this disclosure. Methods for treating viral infections, including Hepatitis C viral infections are provided by the disclosure.
    Type: Application
    Filed: February 20, 2017
    Publication date: June 8, 2017
    Inventors: Jason Allan Wiles, Qiuping Wang, Akihiro Hashimoto, Godwin Pais, Xiangzhu Wang, Venkat Gadhachanda, Avinash Phadke, Milind Deshpande, Dawei Chen
  • Publication number: 20170157097
    Abstract: Pharmaceutical compositions of the invention include novel functionalized 1,3-benzenediols having a disease-modifying action in the treatment of hepatic encephalopathy and related conditions. Pharmaceutical compositions of the invention further include novel neuroprotective agents.
    Type: Application
    Filed: February 20, 2017
    Publication date: June 8, 2017
    Inventors: Douglas E. BRENNEMAN, William Alvin KINNEY, Mark MCDONNELL, Dean PETKANAS
  • Publication number: 20170157098
    Abstract: To provide a Clopidogrel Hydrogen Sulfate solid preparation, melting granulation process is used, the content of raw material in the granules obtained is high, and the preparation is of good homogeneity, smooth surface, small tablet weight variation and dissolution complying with the clinical medication. When specific crystal form is used, the effect is better.
    Type: Application
    Filed: October 3, 2016
    Publication date: June 8, 2017
    Inventors: Yanxia CAI, Yueyao TAN, Guanhao YE
  • Publication number: 20170157099
    Abstract: Described herein are assays for identifying piericidins and piericidin compositions.
    Type: Application
    Filed: November 24, 2014
    Publication date: June 8, 2017
    Applicant: The Regents of the University of California Santa Cruz
    Inventors: Victoria Auerbach Stone, Roger G. Linington, Weng Ruh Wong, Miles C. Duncan
  • Publication number: 20170157100
    Abstract: A method of treating one or more symptoms associated with underactive bladder in a patient suffering therefrom by administering to the patient a therapeutically effective amount of an acetylcholinesterase inhibitor (AChEI) and an amount of a muscarinic receptor agonist effective to reduce the volume of post void residual in the patient obtained by treatment with the AChEI alone.
    Type: Application
    Filed: December 5, 2016
    Publication date: June 8, 2017
    Inventor: Sidney J. Goldfarb
  • Publication number: 20170157101
    Abstract: Provided herein are methods for treating sickle cell disease, comprising administering to a subject 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)-methoxy)benzaldehyde (Compound 1), or a polymorph thereof, in certain dosing regimens.
    Type: Application
    Filed: December 2, 2016
    Publication date: June 8, 2017
    Inventors: Eleanor L. Ramos, Joshua Eli Lehrer-Graiwer, Athiwat Hutchaleelaha
  • Publication number: 20170157102
    Abstract: The present invention relates to Perhexiline, or a pharmaceutically acceptable salt thereof, for use in the treatment of a pathology caused by trematodes.
    Type: Application
    Filed: July 16, 2015
    Publication date: June 8, 2017
    Inventors: Giovina RUBERTI, Cristiana LALLI, Alessandra GUIDI, Alberto BRESCIANI, Nadia GENNARI, Giacomo PAONESSA, Emanuela NIZI
  • Publication number: 20170157103
    Abstract: Provided herein are methods of treating, preventing and/or managing diffuse large B-cell lymphoma (DLBCL), which comprise administering to a patient 3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.
    Type: Application
    Filed: November 30, 2016
    Publication date: June 8, 2017
    Inventors: Anjan Thakurta, Patrick Hagner, Anita Gandhi